Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex*

Andreas Krueger, Ingo Schmitz, Sven Baumann, Peter H. Krammer, and Sabine KirchhoffDagger

From the Tumor Immunology Program, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

Received for publication, February 27, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Upon stimulation, CD95 (APO-1/Fas) recruits the adapter molecule FADD/MORT1, procaspase-8, and the cellular FLICE-inhibitory proteins (c-FLIP) into the death-inducing signaling complex (DISC). According to the induced proximity model, procaspase-8 is activated in the DISC in an autoproteolytic manner by two subsequent cleavage steps. c-FLIP proteins exist as a long (c-FLIPL) and a short (c-FLIPS) splice variant, both of them capable of protecting cells from death receptor-mediated apoptosis. In stably transfected BJAB cells, both c-FLIPS and c-FLIPL block procaspase-8 activation at the DISC. However, cleavage is blocked at different steps. c-FLIPL allows the first cleavage step of procaspase-8, leading to the generation of the p10 subunit. In contrast, c-FLIPS completely inhibits cleavage of procaspase-8. Interestingly, p43-c-FLIPL lacking the p12 subunit also prevents cleavage of procaspase-8. In contrast, a nonprocessable mutant of c-FLIPL allows the first cleavage of procaspase-8. In conclusion, both c-FLIP proteins prevent caspase-8 activation at different levels of procaspase-8 processing at the DISC. Our results indicate that c-FLIPL induces a conformation of procaspase-8 that allows partial but not complete proteolytical processing, whereas in contrast c-FLIPS even prevents partial procaspase-8 activation at the DISC.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apoptosis plays an important role in tissue homeostasis. In the immune system, apoptosis is used for negative and positive selection of T and B cells in the thymus and bone marrow, respectively, and to maintain immune homeostasis (1). Apoptosis can be induced by death receptors, a subgroup of the TNF1/nerve growth factor receptor superfamily (2). The best characterized member of the death receptor subfamily is CD95, also known as APO-1 or Fas. Stimulation of CD95 with its cognate ligand, CD95L, leads to clustering of the monomeric receptor or, as recently suggested, to conformational changes of preformed receptor complexes (3). This enables binding of the adapter molecule FADD/MORT1 (4, 5) and of procaspase-8 (FLICE, MACH, Mch5) (6-8) to CD95 via homophilic death domain and death effector domain (DED) interactions, respectively, forming the death-inducing signaling complex (DISC) (9). Recruitment of procaspase-8 to the DISC leads to its proteolytic activation through several cleavage steps. Free p18 and p10 subunits form the active caspase-8 heterotetramer. Active caspase-8 then initiates a cascade of caspase activation finally leading to cell death (10).

Sensitivity toward CD95-mediated apoptosis can be modulated at different levels in the CD95 signaling pathways (e.g. by the viral caspase inhibitors CrmA or p35 (11-14) or in certain cells (type II cells)) by Bcl-2/Bcl-xL overexpression inhibiting mitochondrial changes during apoptosis (15). Viral FLICE-inhibitory proteins (v-FLIP), which are components of the class of gamma -herpesviruses, form another family of apoptosis-inhibitory molecules. These molecules are composed of two death effector domains, a structure resembling the N-terminal half of procaspase-8. Via DED-DED-interaction, v-FLIP proteins are recruited to the CD95-DISC, preventing procaspase-8 recruitment and processing and thereby CD95-induced apoptosis (16).

A human homolog of v-FLIP is called c-FLIP/FLAME-1/I-FLICE/Casper/CASH/MRIT/CLARP/Usurpin (17-24). On the mRNA level, several c-FLIP splice variants exist. On the protein level, however, only two endogenous forms, c-FLIPL and c-FLIPS, could be detected so far (17, 20, 24, 25). c-FLIPL is structurally similar to procaspase-8, since it contains two death effector domains and a caspase-like domain. However, this domain lacks residues that are important for the catalytic activity of caspase-8, most notably the cysteine within the active site. The short form of c-FLIP, c-FLIPS, structurally resembles v-FLIP.

Despite the analysis of mice deficient for c-FLIP, which indicates a role of c-FLIP in cardiac development (26), the definitive physiological role of this molecule still remains controversial. Recent reports show that high expression of FLIP promotes tumor growth and facilitates immune escape of tumors (27, 28). In addition, mouse embryonic fibroblasts deficient of c-FLIP clearly display an increased sensitivity toward death receptor-mediated apoptosis (26).

Several reports suggest an involvement of c-FLIP in the modulation of the immune response (17, 29-33). We recently demonstrated a potential physiological role for c-FLIPS and found that it is up-regulated upon restimulation of the T cell receptor in primary human T cells. This finding correlates with rescue of these cells from activation-induced cell death (34). In addition, we demonstrated up-regulation of c-FLIPS after CD3/CD28 costimulation, which might contribute to protection toward activation-induced cell death (35).

The mechanism of c-FLIPL function has only been partly elucidated (25). Both procaspase-8 and c-FLIPL are recruited to the DISC. After initial cleavage of both molecules, the cleavage intermediates remain bound to the DISC and can no longer be replaced by procaspase-8. This prevents activation of the cytoplasmic procaspase-8 pool and renders the cell resistant to CD95-induced apoptosis (25). So far, nothing is known about the mechanism of c-FLIPS function.

In a previous study, we found that c-FLIPS, but not c-FLIPL, contributes to rescue from activation-induced cell death in T cells (34, 35). Therefore, we further clarify the mechanisms of apoptosis inhibition mediated by c-FLIPS to detect possible differences compared with c-FLIPL action. To investigate this issue, we generated BJAB clones stably expressing c-FLIPS or c-FLIPL or both. Overexpression of either c-FLIPS or c-FLIPL results in resistance toward death receptor-mediated cell death. The two splice variants, however, cause this effect in a distinct fashion. Thus, procaspase-8 activation is inhibited at two different cleavage steps at the DISC by c-FLIPS and c-FLIPL, respectively, the two splice variants of c-FLIP. A detailed analysis of the domains of c-FLIPL revealed that full-length c-FLIPL, but not a mutant lacking the p12 subunit, contributes to the first cleavage step of caspase-8.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Lines-- The B lymphoblastoid cell line BJAB and the T cell line H9 were maintained in RPMI 1640 (Life Technologies, Inc.), 10 mM HEPES (Life Technologies), 2 mg/ml Gentamycin (Life Technologies), 10% fetal calf serum (Life Technologies) in 5% CO2.

Antibodies and Reagents-- Monoclonal antibodies against FADD (mouse IgG1) and the FLAG epitope (MDYKDDDDK, clone M2, mouse IgG1) were purchased from Transduction Laboratories (Lexington, KY) and Sigma, respectively. The C15 monoclonal antibody (mouse IgG2b) recognizes the p18 subunit of caspase-8 (36), the C5 monoclonal antibody (mouse IgG2a) recognizes the p10 subunit of caspase-8 (36), the anti-c-FLIP monoclonal antibody NF6 (mouse IgG1) was described in (25), and anti-APO-1 is an agonistic monoclonal antibody (IgG3, kappa ) recognizing an epitope on the extracellular part of CD95 (APO-1/Fas) (37). The horseradish peroxidase-conjugated goat anti-mouse IgG1 and IgG2b were from Southern Biotechnology Associates (Birmingham, AL). Leucine zipper (LZ)-TRAIL and LZ-CD95L were produced as described (38). TNFalpha was purchased from Biomol (Plymouth Meeting, PA). All other chemicals used were of analytical grade and purchased from Merck or Sigma.

Isolation of the c-FLIPS Coding Region-- The coding sequence of c-FLIPS was isolated after total RNA isolation of H9 cells, reverse transcriptase-polymerase chain reaction, and subsequent polymerase chain reaction, using the following primer pair: c-FLIP sense, 5'-ggcgaattcATGcccgggTCTGCTGAAGTCATCCATCCAGG-3'; c-FLIPS antisense, 5'-cgtctagaTCACATGGAACAACAATTTCCAAG-3'. The sequences shown in capital letters are homologous to the coding sequence of c-FLIPS. The isolated polymerase chain reaction fragment was cloned into pcDNA3 (Invitrogen); the correct sequence was confirmed by DNA sequencing.

Generation of Expression Vectors-- Expression vectors coding for epitope-tagged proteins were cloned by ligating double-stranded oligonucleotides comprising the sequences of the FLAG epitope (pcDNA3-FLAG) or the Myc epitope (pcDNA3-Myc), respectively, into the pcDNA3 expression vector (Invitrogen). FLAG-c-FLIPS and Myc-c-FLIPS expression constructs were generated by ligating the coding sequence of c-FLIPS in frame into pcDNA3-FLAG or pcDNA3-Myc, respectively. The FLAG-p43mu expression construct coding for amino acids 1-376 of c-FLIPL was generated by standard polymerase chain reaction and cloning techniques using the following primers: 5'-ggcgaattcATGcccgggTCTGCTGAAGTCATCCATCCAGG-3' and 5'-gattctagaTCAATCCACCTCCAAGAGGCTGCTGTCC-3'. The FLAG-D376N expression construct was generated using the primer 5'-CTTGGAGGTGAATGGGCCAGCGATG-3' and the corresponding complementary primer applied in the QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA).

Stable Transfections of BJAB Cells-- Stable transfection of BJAB cells was performed with expression vectors coding c-FLIPS C-terminally fused to the FLAG or Myc epitope tag (pcDNA3-FLAG-c-FLIPS, pcDNA3-Myc-c-FLIPS), FLAG epitope-tagged c-FLIPL (pEFrsFLAG-FLIPL) (25), or the respective empty vectors (control) by electroporation (960 microfarads, 200 V). Selection pressure was added 48 h after transfection (4000 µg/ml G418 and/or 1 µg/ml puromycin; Sigma), and high expressing clones were identified by Western blot analysis using NF6 monoclonal antibody.

DISC Analysis by Immunoprecipitation-- The composition of the CD95 DISC was determined as follows. 5 × 107 cells (if not otherwise indicated) were either treated with 10 µg of LZ-CD95L-containing supernatant for 5 min at 37 °C and then lysed in lysis buffer (30 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, small peptide inhibitors (Sigma), 1% Triton X-100 (Serva), and 10% glycerol) (stimulated condition) or lysed without treatment (unstimulated condition). The CD95 DISC was then precipitated for 2 h or overnight at 4 °C with 2 µg of anti-APO-1 coupled to protein A-Sepharose (Sigma) or 2 µg of anti-FLAG (M2) coupled to protein G-agarose (Roche Molecular Biochemicals). After immunoprecipitation, the beads were washed four times with 20 volumes of lysis buffer.

Western Blot-- For Western blotting, immunoprecipitates or cytosolic proteins equivalent to 106 cells or 20 µg of protein were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to Hybond nitrocellulose membrane (Amersham Pharmacia Biotech), blocked with 5% nonfat dry milk in PBS/Tween (PBS plus 0.05% Tween 20) for at least 1.5 h, washed with PBS/Tween, and incubated with the primary antibody in PBS/Tween for 16 h at 4 °C. Blots were developed with horseradish peroxidase-conjugated secondary antibody diluted 1:20,000 in PBS/Tween. After washing with PBS/Tween, the blots were developed with a chemiluminescence method following the manufacturer's protocol (PerkinElmer Life Sciences).

Cytotoxicity Assay-- For assaying apoptosis, 5 × 105 cells were incubated in 24-well plates with or without the indicated amounts of anti-APO-1 plus 10 ng/ml protein A, LZ-TRAIL, LZ-CD95L, or TNFalpha plus 10 µg/ml cycloheximide in medium for 16 h at 37 °C. Cells were centrifuged briefly in a minifuge (Heraeus) at 4000 rpm for 5 min, washed once with PBS, and resuspended in a buffer containing 0.1% (w/v) sodium citrate, 0.1% (v/v) Triton X-100, and 50 µg/ml propidium iodide (Sigma). After incubation at 4 °C in the dark for at least 16 h, apoptotic nuclei were quantified by FACScan (Becton Dickinson). Specific apoptosis was calculated as follows: (% experimental apoptosis - % spontaneous apoptosis)/(100 - % spontaneous apoptosis) × 100.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

c-FLIPS Inhibits CD95-mediated Apoptosis in BJAB Cells-- Recently, c-FLIPS and c-FLIPL were described as inhibitors of death receptor-mediated apoptosis (17). However, the molecular mechanisms of c-FLIP action remained largely elusive. To study the mechanisms of apoptosis inhibition mediated by c-FLIPS and c-FLIPL in detail, we generated BJAB cells stably transfected with expression constructs coding either for N-terminally FLAG-tagged c-FLIPS, N-terminally Myc-tagged c-FLIPS, or N-terminally FLAG-tagged c-FLIPL alone or in combination with Myc-tagged-c-FLIPS (FL/MS) (see Fig. 1A for expression constructs). BJAB cell clones expressing low, intermediate or high amounts of FLAG-tagged c-FLIPS were identified by Western blotting (Fig. 1B, left) as well as clones expressing high concentrations of FLAG-tagged-c-FLIPL or Myc-tagged c-FLIPS alone or in combination (FL/MS; Fig. 1B, right). To exclude clonal effects due to different death receptor expression, we determined cell surface expression of TRAILR1, TRAILR2, TRAILR3, TRAILR4, TNFR1, and CD95. We also determined expression of procaspase-8 and FADD. The expression patterns of these proteins were comparable (data not shown). To analyze the antiapoptotic function of the transfected c-FLIP proteins, we investigated the sensitivity of these BJAB cell clones toward death receptor-mediated apoptosis. Overexpression of c-FLIPS resulted in cells resistant toward CD95-mediated apoptosis, induced by LZ-CD95L, as well as resistance toward TNFalpha - and TRAIL-mediated apoptosis. Resistance directly correlated with the amounts of c-FLIPS (Fig. 1C). However, the cells were still sensitive toward staurosporine-induced apoptosis (data not shown (17)). Overexpression of c-FLIPL and c-FLIPS simultaneously resulted in increased inhibition toward CD95-mediated apoptosis in an additive manner as compared with cells expressing c-FLIPL or c-FLIPS alone (Fig. 1D). TRAIL- and TNFalpha -mediated apoptosis were completely inhibited. We conclude from these results that the CD95 DISC was not saturated with c-FLIP proteins in the single transfected cells, and therefore an additive effect in cells expressing both c-FLIP proteins was observed. In contrast, c-FLIP expression levels in the single transfected BJAB cells were sufficient for blocking of TRAIL- and TNFalpha -mediated apoptosis in BJAB cells, which might be due to lower expression levels of receptors for TRAIL and TNFalpha as compared with CD95.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   c-FLIP proteins inhibit CD95-mediated apoptosis in BJAB cells. A, overview of tagged c-FLIP expression constructs used for stable expression in BJAB cells. The numbers indicate amino acids. B, Western blot analysis of lysates of BJAB cells stably transfected with expression vectors coding for the indicated FLIP proteins or vector control. Lanes 1 and 5, vector-transfected cells (Control); lanes 2-4, FLAG-tagged c-FLIPS; lane 6, FLAG-tagged c-FLIPL; lane 7, Myc-tagged c-FLIPS; lane 8, Myc-tagged c-FLIPS and FLAG-tagged c-FLIPS (FL/MS). The tagged c-FLIP proteins migrate with reduced mobility compared with the endogenous ones. C, BJAB cells described in B were incubated with the indicated concentrations of LZ-CD95L, TNFalpha , or LZ-TRAIL for 16 h. Apoptosis was measured by the amount of DNA-fragmentation. D, BJAB cells described for B were incubated with the indicated concentrations of LZ-CD95L, TNFalpha , or LZ-TRAIL for 16 h. Apoptosis was measured as described for C. One representative experiment out of five is shown.

c-FLIPS Completely Blocks Cleavage of Procaspase-8-- To investigate the molecular mechanisms of c-FLIPS-mediated apoptosis inhibition, we determined activation of procaspase-8 as one of the first detectable events upon CD95 triggering. In vector-transfected cells, procaspase-8 was completely processed, and the p10 and p18 active subunits were detectable after 10-30 min (Fig. 2B, lane 3; for the procaspase-8 cleavage pattern, also compare Fig. 2A). In contrast, the generation of active subunits was completely inhibited in cells overexpressing c-FLIPS. Neither the p18 nor the p10 subunits were detectable, and uncleaved procaspase-8 was detectable over a period of up to 3 h (Fig. 2B, lane 18). In cells expressing c-FLIPL, the generation of the p18 subunit was blocked, and only small amounts of the p10 subunit of procaspase-8 were generated (Fig. 2B, lanes 7-12). In the latter case, c-FLIPL only allowed the p43/41 cleavage product of caspase-8 to be generated. The p43/41 cleavage product stays at the DISC, thereby preventing recruitment and activation of cytosolic procaspase-8. Similar to procaspase-8, c-FLIPL is also cleaved at the DISC by either procaspase-8 or its p43/41 cleavage product (Fig. 2B, lanes 8-12). Thus, both c-FLIP proteins block the generation of active caspase-8. Our results suggest that c-FLIPS completely prevents procaspase-8 cleavage, whereas c-FLIPL allows the first cleavage step of procaspase-8.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 2.   Different procaspase-8 cleavage products upon CD95 triggering in the presence of c-FLIPS or c-FLIPL. A, simplified model for procaspase-8 processing. Procaspase-8 processing occurs in two consecutive steps: the generation of the p10 and the p43/41 subunits (1) and processing of the p43/41 cleavage product into the prodomain and the p18 subunit (2). B, time course of procaspase-8 and c-FLIPL processing in BJAB cells stably expressing FLAG-tagged c-FLIPS (lanes 13-18) or FLAG-tagged c-FLIPL (lanes 7-12) demonstrated in Fig. 1B. Control, BJAB cells tranfected with empty vector (lanes 1-6).

c-FLIPS Completely Blocks DISC Activity-- Since both procaspase-8 and c-FLIPS are recruited into the DISC (25), we assumed that in the presence of c-FLIPS procaspase-8 cleavage is blocked at the DISC or that its recruitment is completely inhibited. Therefore, we performed a DISC analysis by immunoprecipitation of either CD95-unstimulated or -stimulated BJAB cells that were either transfected with c-FLIP or vector alone, and we determined DISC-associated caspase-8 cleavage products by Western blot analysis. In cells overexpressing c-FLIPS, only unprocessed procaspase-8 was detectable in the DISC (Fig. 3, lane 6). In addition, cleavage of c-FLIPL was also significantly reduced (Fig. 3, lane 6). That was also found in cellular lysates (compare Fig. 2B). In contrast, the presence of c-FLIPL did not prevent the generation of the p43/41 cleavage product of caspase-8. This finding explains the detection of the p10 caspase-8 subunit in cellular lysates. FADD recruitment to the DISC was not modulated in the presence of c-FLIPL or c-FLIPS. In summary, c-FLIPS blocks cleavage of procaspase-8 at the DISC, whereas c-FLIPL prevents further processing of the p43/41 cleavage product.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 3.   Differences in procaspase-8 processing in the presence of c-FLIPS or c-FLIPL at the DISC. DISC analysis of BJAB cells stably transfected with empty vector (Control, lanes 1 and 2), FLAG-tagged c-FLIPL (lanes 3 and 4), or Myc-tagged c-FLIPS (lanes 5 and 6) encoding expression plasmids, triggered with 10 µg of LZ-CD95L (+) or left untriggered (-).

The First Cleavage Step of Procaspase-8 Activation Is Driven by Full-length c-FLIPL-- The fact that the p43 cleavage form of c-FLIPL is the predominant form at the DISC upon CD95 triggering (see Ref. 25 and Fig. 3), suggested that cleavage of c-FLIPL is important for blocking caspase-8 activation. To analyze the mechanism of procaspase-8 cleavage inhibition by c-FLIPL in more detail, we generated expression constructs coding for N-terminally FLAG-tagged mutants of c-FLIPL which either resemble the p43 cleavage form lacking the p12 subunit of c-FLIPL entirely (FLAG-p43mu) or contain a defective cleavage site (FLAG-D376N) (20) (compare Fig. 4A and scheme in Fig. 6). BJAB cells stably transfected with these expression constructs or empty vector were identified by Western blotting (Fig. 4B), and the sensitivity toward CD95-mediated apoptosis was investigated. Overexpression of either FLAG-tagged p43-c-FLIPL (p43mu) or FLAG-tagged unprocessable c-FLIPL (D376N) resulted in cells resistant toward LZ-CD95L-induced apoptosis (Fig. 4C). Therefore, both the full-length and the p43 cleavage form of c-FLIPL act in an antiapoptotic manner and block CD95-mediated apoptosis. Thus, cleavage of c-FLIPL is not required for its antiapoptotic function.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Full-length c-FLIPL is required for procaspase-8 processing. A, overview of FLAG-tagged c-FLIPL expression constructs containing the sequence of unprocessable c-FLIPL (D376N) or the truncated c-FLIPL (p43mu) used for stable expression in BJAB cells. The numbers indicate the amino acids in the resulting proteins. B, Western blot analysis of lysates of BJAB cells stably transfected with expression vectors coding for the indicated FLIP proteins. Lane 1, vector-transfected cells (Control); lane 2, FLAG-tagged p43-c-FLIPL (p43mu); lane 3, FLAG-tagged unprocessable c-FLIPL (D376N). C, BJAB cells described for B were incubated with the indicated concentrations of LZ-CD95L. Apoptosis was measured by the amount of DNA degradation. D, time course of procaspase-8 and c-FLIPL processing in BJAB cells stably expressing D376N (lanes 7-12) or p43mu (lanes 13-18) demonstrated in A and B. Control, BJAB cells tranfected with empty vector (lanes 1-6). E, DISC analysis of BJAB cells shown in A-D triggered with 10 µg of LZ-CD95L (+) or left untriggered (-).

To determine the step in apoptosis signaling at which the mutated c-FLIPL molecules inhibit cleavage of procaspase-8, we looked for cleavage products after CD95 triggering. In vector (control)-transfected cells, procaspase-8 was completely processed, and the p10 and p18 active subunits were detectable (Fig. 4D, lanes 1-6). In cells transfected with an expression construct coding for the FLAG-tagged p43 cleavage product of c-FLIPL (p43mu), the generation of the p10 subunit was delayed and not detectable after 10 min (Fig. 4D, lane 4). In contrast, in cells overexpressing FLAG-tagged uncleavable c-FLIPL (D376N), procaspase-8 was cleaved into its p43/41 and p10 subunits within the first 10 min of stimulation (Fig. 4D, compare lanes 8 and 14). The p18 subunit was not generated in the presence of both c-FLIPL mutants (Fig. 4D). Thus, blocking of procaspase-8 cleavage by p43mu and the D376N mutant occurred at different steps. To study this phenomenon in more detail, we performed DISC analysis of vector- or c-FLIP mutant-transfected BJAB cells and tested for associated caspase-8 cleavage products by Western blot analysis. In vector-transfected cells, both the full-length caspase-8 and the p43/p41-caspase-8 form were detectable in the DISC. In contrast, in D376N-expressing cells, only the p43/41 cleavage products of caspase-8 could be detected, thus resembling the composition of the DISC in the presence of high amounts of wild-type c-FLIPL. The presence of p43mu inhibited the generation of the active caspase-8 subunits, which explains our findings presented in Fig. 4D and resembles the DISC in c-FLIPS high expressing cells. These results indicate that the presence of full-length c-FLIPL but not cleavage of c-FLIPL is necessary for the initial cleavage of procaspase-8 in the presence of high amounts of c-FLIPL.

c-FLIPL and c-FLIPS Coexist in the Same DISC-- Since high expression of either c-FLIPL or c-FLIPS blocks procaspase-8 processing at different cleavage steps, we asked whether the presence of either c-FLIPL or c-FLIPS in one DISC would exclude the respective other splice variant from recruitment. Therefore, we precipitated FLAG-tagged c-FLIPL in LZ-CD95L-triggered BJAB cells to isolate the DISCs containing FLAG-tagged c-FLIPL and looked for recruitment of Myc-tagged c-FLIPS to the DISC. Precipitation of the DISC upon CD95 triggering via FLAG-tagged c-FLIPL resulted in coimmunoprecipitation of Myc-tagged c-FLIPS in the double-transfected cells (Fig. 5, lane 6). In addition, we isolated the DISC via precipitation of CD95 in the double-transfected BJAB cells as described above (Fig. 5, lanes 3 and 4). Both c-FLIPL and c-FLIPS were detected in the DISC, and FADD recruitment was not impaired when compared with DISC formation in the vector-transfected cells. These results suggest that upon CD95 triggering, c-FLIPS and c-FLIPL can coexist in the same DISC. However, in view of the techniques used, our data do not exclude DISC species containing only one form of c-FLIP.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 5.   c-FLIPL and c-FLIPS coexist in the same DISC. DISC analysis of BJAB cells stably transfected with empty vector (Control, lanes 1 and 2) or FLAG-tagged c-FLIPL and Myc-tagged c-FLIPS (FL/MS, lanes 3 and 4) expression plasmids, triggered with 10 µg of LZ-CD95L (+) or left untriggered (-). DISC was precipitated (I.P.) either by using anti-APO-1 (lanes 1-4) or anti-FLAG antibodies (lanes 5 and 6). BJAB cells containing the empty vector were used as the control (lanes 1 and 2).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The apoptosis-inducing signal transduction pathways of the CD95 system have been well characterized (39). In contrast, much less is known about mechanisms of inhibition of CD95-mediated apoptosis. One protein that has an inhibitory function on the DISC by reducing the generation of active caspase-8 is c-FLIPL. However, its mechanism of inhibition is not well understood. A second cellular splice variant of c-FLIP, c-FLIPS, also has antiapoptotic effects. Both c-FLIP proteins contain two DEDs and are recruited into the DISC and thereby block death receptor-mediated apoptosis. In this report, we provide important insight into the molecular mechanisms of c-FLIP-mediated apoptosis inhibition. BJAB cells that express high amounts of either c-FLIPL or c-FLIPS are protected against death receptor-mediated apoptosis. The presence of c-FLIPS prevents the initial cleavage step of procaspase-8, and therefore, its full-length form can be detected at the DISC. In contrast, c-FLIPL allows the initial cleavage step but blocks further processing and thus the generation of the p18 subunit. The difference in processing of procaspase-8 in the presence of the two c-FLIP splice variants is also reflected in cell lysates and sheds new light on caspase-8 activation at the DISC. From these results, we suggest the following model of c-FLIP proteins mediated inhibition of death receptor initiated apoptosis. In the presence of low concentrations of c-FLIP proteins, procaspase-8 represents the majority of tandem DED-containing proteins at the DISC and is activated by trans- and autocatalytical cleavage due to the close proximity of several procaspase-8 molecules (Fig. 6B; Ref 40). c-FLIPL that is recruited into the DISC is cleaved by caspase-8. High amounts of c-FLIPL in the DISC abolish the close proximity of procaspase-8 molecules, instead leading to proximity of c-FLIPL and procaspase-8, resulting in the first but not the second step of procaspase-8 processing. In this conformation, only the p10 subunit of caspase-8 and the p12 subunit of c-FLIPL are generated (Fig. 6C). Since c-FLIPL itself has no intrinsic catalytic activity, the generation of the p10 subunit of caspase-8 proceeds autocatalytically, whereas the generation of the p18 subunit would require transcatalytical actvity (Fig. 6C). High amounts of c-FLIPS in the DISC totally prevent procaspase-8 cleavage (Fig. 6D). This indicates that c-FLIPL, in contrast to c-FLIPS, still induces a conformation of the DISC that leads to autocatalytic activity of procaspase-8 and the first cleavage step. This hypothesis is supported by the cleavage pattern of procaspase-8 in the presence of c-FLIPL mutants. The uncleavable c-FLIPL mutant, like the wild-type c-FLIPL, allows the generation of the p10 subunit of caspase-8. Therefore the full-length protein of c-FLIPL, but not its cleavage, facilitates the first cleavage step of procaspase-8 (Fig. 6F). Our results are further supported by the observation that the deletion mutant of c-FLIPL that does not contain the p12 subunit (p43mu) prevents the first cleavage step of procaspase-8, similar to c-FLIPS (Fig. 6E). Both the p43 cleavage product of c-FLIPL and the uncleaved form block caspase-8 activation and, therefore, inhibit apoptosis. Given that procaspase-8 interacts with c-FLIP proteins in the DISC in a dimeric manner, our results suggest that the generation of the p10 subunit of caspase-8 occurs autocatalytically. In contrast, the second cleavage step leading to release of the p18 subunit requires transcatalytic activity. However, our results do not exclude interactions of dimers with dimers due to the multimeric nature of death receptor complexes.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Model for c-FLIP mediated inhibition of procaspase-8 processing at the DISC. A, triggering of CD95 leads to the recruitment of FADD, procaspase-8, and c-FLIP proteins into the DISC. Binding of procaspase-8 results in its activation by auto- and transproteolytic cleavage. The remaining caspase-8 prodomain is replaced by uncleaved procaspase-8, which is processed in the same manner as described above. B-F, depending on the ratio of procaspase-8 and c-FLIP proteins at the DISC (gray box), different products are released from the DISC upon receptor triggering. B, low amounts of c-FLIP proteins allow processing of procaspase-8, leading to formation of the active caspase-8 heterotetramer composed of the p18 and p10 subunits. C, in the presence of high amounts of c-FLIPL, procaspase-8 is recruited into the DISC, and cleavage is blocked after the generation of the p43 cleavage products of both caspase-8 and c-FLIPL. D, in the presence of high amounts of c-FLIPS, procaspase-8 is recruited into the DISC but remains unprocessed. In each case, modulation of caspase-8 cleavage renders cells resistant to CD95-mediated cell death. E, high amounts of truncated c-FLIPL-p43mu prevent procaspase-8 processing completely. F, expression of unprocessable c-FLIPL-D376N allows initial cleavage of procaspase-8 but prevents further processing, leading to accumulation of p43/41-caspase-8 in the DISC.

High expression of c-FLIPS also prevents cleavage of c-FLIPL at the DISC. This phenomenon was also detected in restimulated primary T cells (34). It may be due to spatial interference of c-FLIPS with the interaction of procaspase-8 and c-FLIPL. Another possibility is that initial cleavage of procaspase-8, blocked by c-FLIPS, is required for its transcatalytic activity and, thus, c-FLIPL is not cleaved at the DISC upon high expression of c-FLIPS.

Transfectants expressing FLAG-tagged c-FLIPL and Myc-tagged c-FLIPS showed an additive effect with respect to protection against CD95-mediated apoptosis. This indicates that DISCs in single transfectants are not saturated for c-FLIP binding. In addition, p43/41-caspase-8 could be detected in the DISC, which was not the case in c-FLIPS single transfectants. This could be explained by either a dominant function of c-FLIPL over c-FLIPS or, alternatively, by caspase-8 cleavage in DISC species containing c-FLIPL alone.

Since both c-FLIP splice variants act as antiapoptotic proteins, the question arises why certain physiological stimuli exclusively induce either c-FLIPL or c-FLIPS, like BCR/CD40 (32, 33) or TCR/CD28 (34, 35), respectively. Therefore, the biological function of different procaspase-8 cleavage patterns remains to be elucidated. Since c-FLIPS totally prevents cleavage of both caspase-8 and c-FLIPL, one might speculate that the generation of these cleavage products is blocked because they are necessary for the recruitment of yet to be identified molecules into the DISC or, alternatively, they prevent the association of unidentified molecules.

Recently, it was reported that certain, but not all, viral and cellular FLIP proteins enhance activation of the NF-kappa B and AP-1 pathways upon stimulation of death receptors, possibly via recruitment of RIP, TRAF1, and TRAF2 into the DISC (41-43). However, one study also shows suppressive effects of DED-containing proteins, such as c-FLIP, on the NF-kappa B pathway (44). Therefore, the role of c-FLIP in activation of NF-kappa B by death receptors needs to be addressed in more detail.

    ACKNOWLEDGEMENTS

We thank A. Strasser for providing the pEFrs-FLAG expression vector and H. Walczak for providing LZ-TRAIL. We are grateful to Marcus E. Peter for helpful discussions in the initial phase of this study. We thank Wendelin Wolf for technical assistance and Heidi Sauter for expert secretarial assistance.

    FOOTNOTES

* This work was supported by Grants from Sonderforschungsbereich der deutschen Forschungsgemeinschatz 601 and 405, Deutsches Krebsforschungszentrum/Israeli Minister of Science (DKFZ/MOS) (Ca 86), Deutsch-Israelische Projektkooperation, and the Sander Stiftung.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 49 6221 423765; Fax: 49 6221 411715; E-mail: S.Kirchhoff@dkfz-heidelberg.de.

Published, JBC Papers in Press, March 5, 2001, DOI 10.1074/jbc.M101780200

1 The abbrevations used are: TNF, tumor necrosis factor; CD95L, CD95 ligand; FLICE, FADD-like interleukin-1beta -converting enzyme; FADD, Fas-associated death domain; DED, death effector domain; DISC, death-inducing signaling complex; FLIP, FLICE-inhibitory protein; TRAIL, TNF-related apoptosis-inducing ligand; LZ, leucine zipper; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Krammer, P. H. (2000) Nature 407, 789-795[CrossRef][Medline] [Order article via Infotrieve]
2. Peter, M. E., Scaffidi, C., Medema, J. P., Kischkel, F. C., and Krammer, P. H. (1998) in Apoptosis: Problems and Diseases (Kumar, S., ed) , pp. 25-63, Springer, Heidelberg
3. Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K., Johnson, M., Lynch, D., Tsien, R. Y., and Lenardo, M. J. (2000) Science 288, 2354-2357[Abstract/Free Full Text]
4. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. (1995) J. Biol. Chem. 270, 7795-7798[Abstract/Free Full Text]
5. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81, 505-512[Medline] [Order article via Infotrieve]
6. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827[Medline] [Order article via Infotrieve]
7. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815[Medline] [Order article via Infotrieve]
8. Srinivasula, S. M., Fernandes-Alnemri, T., Zangrilli, J., Robertson, N., Armstrong, R. C., Wang, L., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. S. (1996) J. Biol. Chem. 271, 27099-27106[Abstract/Free Full Text]
9. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) EMBO J. 14, 5579-5588[Abstract]
10. Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P. H., and Peter, M. E. (1997) EMBO J. 16, 2794-2804[Abstract/Free Full Text]
11. Tewari, M., and Dixit, V. M. (1995) J. Biol. Chem. 270, 3255-3260[Abstract/Free Full Text]
12. Los, M., Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Droge, W., Krammer, P. H., Fiers, W., and Schulze-Osthoff, K. (1995) Nature 375, 81-83[CrossRef][Medline] [Order article via Infotrieve]
13. Enari, M., Hug, H., and Nagata, S. (1995) Nature 375, 78-81[CrossRef][Medline] [Order article via Infotrieve]
14. Xue, D., and Horvitz, H. R. (1995) Nature 377, 248-251[CrossRef][Medline] [Order article via Infotrieve]
15. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998) EMBO J. 17, 1675-1687[Abstract/Free Full Text]
16. Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J. L., Schröter, M., Scaffidi, C., Krammer, P. H., Peter, M. E., and Tschopp, J. (1997) Nature 386, 517-521[CrossRef][Medline] [Order article via Infotrieve]
17. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Nature 388, 190-195[CrossRef][Medline] [Order article via Infotrieve]
18. Srinivasula, S. M., Ahmad, M., Ottilie, S., Bullrich, F., Banks, S., Wang, Y., Fernandes-Alnemri, T., Croce, C. M., Litwack, G., Tomaselli, K. J., Armstrong, R. C., and Alnemri, E. S. (1997) J. Biol. Chem. 272, 18542-18545[Abstract/Free Full Text]
19. Hu, S., Vincenz, C., Ni, J., Gentz, R., and Dixit, V. M. (1997) J. Biol. Chem. 272, 17255-17257[Abstract/Free Full Text]
20. Shu, H.-B., Halpin, D. R., and Goeddel, D. V. (1997) Immunity 6, 751-763[Medline] [Order article via Infotrieve]
21. Goltsev, Y. V., Kovalenko, A. V., Arnold, E., Varfolomeev, E. E., Brodianskii, V. M., and Wallach, D. (1997) J. Biol. Chem. 272, 19641-19644[Abstract/Free Full Text]
22. Han, D. K. M., Chaudhary, P. M., Wright, M. E., Friedman, C., Trask, B. J., Riedel, R. T., Baskin, D. G., Schwartz, S. M., and Hood, L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11333-11338[Abstract/Free Full Text]
23. Inohara, N., Koseki, T., Hu, Y., Chen, S., and Nunez, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10717-10722[Abstract/Free Full Text]
24. Rasper, D. M., Vaillancourt, J. P., Hadano, S., Houtzager, V. M., Seiden, I., Keen, S. L., Tawa, P., Xanthoudakis, S., Nasir, J., Martindale, D., Koop, B. F., Peterson, E. P., Thornberry, N. A., Huang, J., MacPherson, D. P., Black, S. C., Hornung, F., Lenardo, M. J., Hayden, M. R., Roy, S., and Nicholson, D. W. (1998) Cell Death Differ. 5, 271-288[CrossRef][Medline] [Order article via Infotrieve]
25. Scaffidi, C., Schmitz, I., Krammer, P. H., and Peter, M. E. (1999) J. Biol. Chem. 274, 1541-1548[Abstract/Free Full Text]
26. Yeh, W. C., Itie, A., Elia, A. J., Ng, M., Shu, H. B., Wakeham, A., Mirtsos, C., Suzuki, N., Bonnard, M., Goeddel, D. V., and Mak, T. W. (2000) Immunity 12, 633-642[Medline] [Order article via Infotrieve]
27. Medema, J. P., de Jong, J., van Hall, T., Melief, C. J., and Offringa, R. (1999) J. Exp. Med. 190, 1033-1038[Abstract/Free Full Text]
28. Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., and Grandien, A. (1999) J. Exp. Med. 190, 1025-1032[Abstract/Free Full Text]
29. Refaeli, Y., Van Parijs, L., London, C. A., Tschopp, J., and Abbas, A. K. (1998) Immunity 8, 615-623[Medline] [Order article via Infotrieve]
30. Algeciras-Schimnich, A., Griffith, T. S., Lynch, D. H., and Paya, C. V. (1999) J. Immunol. 162, 5205-5211[Abstract/Free Full Text]
31. Van Parijs, L., Refaeli, Y., Abbas, A. K., and Baltimore, D. (1999) Immunity 11, 763-770[Medline] [Order article via Infotrieve]
32. Hennino, A., Berard, M., Casamayor-Palleja, M., Krammer, P. H., and Defrance, T. (2000) J. Immunol. 165, 3023-3030[Abstract/Free Full Text]
33. Wang, J., Lobito, A. A., Shen, F., Hornung, F., Winoto, A., and Lenardo, M. J. (2000) Eur. J. Immunol. 30, 155-163[CrossRef][Medline] [Order article via Infotrieve]
34. Kirchhoff, S., Müller, W. W., Krueger, A., Schmitz, I., and Krammer, P. H. (2000) J. Immunol. 165, 6293-6300[Abstract/Free Full Text]
35. Kirchhoff, S., Müller, W. W., Li-Weber, M., and Krammer, P. H. (2000) Eur. J. Immunol. 30, 2765-2774[CrossRef][Medline] [Order article via Infotrieve]
36. Scaffidi, C., Medema, J. P., Krammer, P. H., and Peter, M. E. (1997) J. Biol. Chem. 272, 26953-26958[Abstract/Free Full Text]
37. Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K. M., and Krammer, P. H. (1989) Science 245, 301-305[Medline] [Order article via Infotrieve]
38. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C., and Lynch, D. H. (1999) Nat. Med. 5, 157-163[CrossRef][Medline] [Order article via Infotrieve]
39. Schmitz, I., Kirchhoff, S., and Krammer, P. H. (2000) Int. J. Biochem. Cell Biol. 32, 1123-1136[CrossRef][Medline] [Order article via Infotrieve]
40. Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S., and Dixit, V. M. (1998) J. Biol. Chem. 273, 2926-2930[Abstract/Free Full Text]
41. Chaudhary, P. M., Eby, M. T., Jasmin, A., Kumar, A., Liu, L., and Hood, L. (2000) Oncogene 19, 4451-4460[CrossRef][Medline] [Order article via Infotrieve]
42. Chaudhary, P. M., Jasmin, A., Eby, M. T., and Hood, L. (1999) Oncogene 18, 5738-5746[CrossRef][Medline] [Order article via Infotrieve]
43. Kataoka, T., Budd, R. C., Holler, N., Thome, M., Martinon, F., Irmler, M., Burns, K., Hahne, M., Kennedy, N., Kovacsovics, M., and Tschopp, J. (2000) Curr. Biol. 10, 640-648[CrossRef][Medline] [Order article via Infotrieve]
44. Wajant, H., Haas, E., Schwenzer, R., Muhlenbeck, F., Kreuz, S., Schubert, G., Grell, M., Smith, C., and Scheurich, P. (2000) J. Biol. Chem. 275, 24357-24366[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.